바이오시밀러 모노클로널 항체 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Biosimilar Monoclonal Antibody Market size is expected to reach USD 107.29 Billion in 2034 from USD 17.01 Billion (2025) growing at a CAGR of 22.71% during 2026-2034.

The Global Biosimilar Monoclonal Antibody Market is witnessing strong growth as healthcare systems seek cost-effective alternatives to expensive biologic therapies. Biosimilars offer similar safety and efficacy profiles compared to reference biologics, making them attractive options for treating chronic diseases such as cancer and autoimmune disorders. The expiration of patents for several blockbuster monoclonal antibodies has accelerated market expansion.

Key growth drivers include increasing healthcare expenditure, supportive regulatory frameworks, and rising demand for affordable biologic treatments. Growing prevalence of chronic diseases and expanding patient populations are encouraging pharmaceutical companies to invest in biosimilar development. Advances in bioprocessing technologies and manufacturing capabilities are also enhancing production efficiency.

Future prospects appear promising as more biosimilars gain regulatory approvals across developed and emerging markets. Increased competition is expected to reduce treatment costs and improve patient access to advanced therapies. Ongoing research collaborations and strategic partnerships among biotechnology firms will likely strengthen the pipeline, ensuring sustained growth in the biosimilar monoclonal antibody market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• Trastuzumab
• Others

By Indication

• Oncology
• Autoimmune Diseases
• Others

By End User

• Hospitals
• Cancer Treatment Centers
• Others

COMPANIES PROFILED

• Teva Pharmaceutical Industries Limited, Coherus BioSciences Inc, Shanghai Henlius Biotech Inc, Celltrion Healthcare Co Ltd, BIOCAD, Pfizer Inc, Amgen Inc, Biocon, Biogen, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Adalimumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bevacizumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infliximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Rituximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Trastuzumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Limited
  • 9.2.2 Coherus BioSciences Inc
  • 9.2.3 Shanghai Henlius Biotech Inc
  • 9.2.4 Celltrion Healthcare Co. Ltd
  • 9.2.5 BIOCAD
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Biocon
  • 9.2.9 Biogen
  • 9.2.10 Novartis AG